Zdrowie i gospodarka · 17/12/1997
FDA Reclassifies Tumor-Associated Antigen Immunological Test Systems
The FDA is reclassifying tumor-associated antigen immunological test systems from class III to class II, allowing for greater market access, after issuing a letter to Centocor, Inc. regarding serum tumor markers.
Source: Federal Register — Food and Drug AdministrationOpen original release →